Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $72.64 Average Target Price from Analysts
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1-year […]
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1-year […]
